Windlas Biotech Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ajemnp0mhsaeyjz6pgietrar.pdf

Key Takeaways


Injectable Facility: The Revenue Is in the Warehouse

Hitesh Windlass: "We have got very, very good and very strong positive reviews from customer audits that have happened. And we have already purchased orders against which we are manufacturing just because we cannot sell before the stability data is finished."

Trade Generics & Institutional: The Growth Engine

Hitesh Windlass: "Does India need 13,000 players? I don't think so. No other country in the world has this kind of a fragmented contract manufacturing industry in pharma."

CDMO & Exports: Steady Contribution


Capacity Expansion: Building Toward Rs. 1,000 Crore


Margins & Costs: The Moving Parts


Capital Allocation: Acquisition Hunt with Patience

Komal Gupta: "We have been looking for the acquisition possibilities... we don't want to rush it, we don't want to be too desperate. If we see issues, we back off."

Guidance & Commitments

CommitmentSpecificsTimeline
Injectable revenue commencementRevenue begins as stability batches clear product by product; small portion in Q3, more in Q4Q3 FY25 onward
Plant-2 expansion fully operationalExpansion complete and contributingQ3 FY25
Plant-6 refurbishment and validationBrownfield facility ready for productionQ1 or Q2 FY26
Plant-6 CAPEX estimateManagement to provide estimated CAPEXNext quarter
EBITDA margin improvement2-3% growth in EBITDA margins expectedNot specified
Revenue capacity targetPlant-2 expansion plus Plant-6 to support Rs. 1,000 crore revenueWhen both facilities are operational
Next site addition triggerWhen Plant-6 and Plant-2 extension reach 45-50% capacity utilizationConditional on utilization
Injectable business evaluationManagement requests evaluation at year-end due to OPEX variabilityEnd of FY25
FY26 CAPEX beyond maintenance and Plant-6No other big CAPEX requirementFY26

Key Metrics

MetricQ2 FY25
Revenue₹187 crores, +22% YoY
H1 FY25 Revenue₹362 crores, +22% YoY
EBITDA₹23 crores, +23% YoY
H1 FY25 EBITDA₹44 crores, +23% YoY
PAT₹16 crores, +12% YoY
H1 FY25 PAT₹29 crores, +12% YoY
EPS₹7.49 in Q2 FY25, +11% YoY; ₹13.97 in H1 FY25
CDMO vertical revenue₹136.3 crores, +16% YoY
Trade generics and institutional revenue₹41.9 crores, +48% YoY
Exports revenue₹8.8 crores, +35% YoY
Liquidity position₹200 crores as on 30th September 2024, after ₹48 crores CAPEX in H1
H1 FY25 CAPEX₹48 crores incurred, ₹38 crores cash outflow
Plant-2 expansion total CAPEX₹33-34 crores, of which ₹26 crores spent by September end
Plant-6 acquisition cost₹17 crores incurred
Dividend paid₹5.5 per share, amounting to ₹11.5 crores for FY24, paid in October 2024